Cymbalta 30mg. 60mg Capsule
PDF Leaflet Revision Date: 24 January 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of depression and Diabetic Peripheral Neuropathic Pain.
Dosage (summary)
60 mg once daily; initial dose 30 mg for renal/hepatic impairment.
Onset of Action / Duration
Onset: 2-4 weeks, Duration: Not specified.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Not recommended during pregnancy; not safe for breastfeeding.
Key Drug Interactions
- MAOIs
- CYP1A2 inhibitors
- CYP2D6 inhibitors
- Serotonergic medicines
Contraindications
- Hypersensitivity to duloxetine
- Severe hepatic impairment
- Advanced renal impairment
- Concomitant MAOIs
- Patients under 18 years
Common side effects
- Nausea
- Headache
- Dry mouth
- Somnolence
- Dizziness
Counselling Points
- Avoid abrupt discontinuation
- Monitor for suicidal thoughts
- Caution with alcohol
- Report any distressing thoughts
Serious warnings
- Risk of suicide
- Serotonin syndrome
- Increased blood pressure
- Hyponatraemia
Important Disclaimer
The Cymbalta 30mg. 60mg Capsule professional information leaflet below is the property of Eli Lilly and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
